NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax Scientific Advisory Board Expansion with Global Vaccine Experts
TL;DR
GeoVax strengthens its competitive edge by adding top vaccine and immunology experts to its advisory board, accelerating development of vaccines for underserved populations and cancers.
GeoVax expanded its Scientific Advisory Board with experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised medicine to guide its MVA platform and clinical strategy.
GeoVax's enhanced advisory board focuses on developing vaccines that protect vulnerable populations in low-income countries and immunocompromised patients, aiming for more equitable global health outcomes.
GeoVax assembled a dream team of vaccine experts including Oxford's Teresa Lambe and T-cell mapping pioneer Alessandro Sette to tackle infectious diseases and cancers.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced an update to its Scientific Advisory Board by welcoming four internationally recognized experts in vaccine design, T-cell immunology, viral pathogenesis, and immunocompromised-host medicine to support its development efforts.
This strategic expansion strengthens GeoVax's position in vaccine innovation by bringing together experts whose combined experience in antigen design, human immunology, and clinical translation aligns with the company's mission to deliver durable, broad-spectrum protection to global and immunocompromised populations.
The new members are: Dr. Alessandro Sette (T-cell epitope mapping expert), Prof. Lance Turtle (viral pathogenesis specialist), Prof. Thushan I. de Silva (human viral immunology expert), and Dr. Joshua A. Hill (vaccine response in immunocompromised patients expert). They join previously appointed Prof. Teresa Lambe.
They bring expertise in T-cell epitope mapping and immune correlates of protection (Dr. Sette), viral pathogenesis and post-infection immune recovery (Prof. Turtle), human viral immunology and global immunosurveillance (Prof. de Silva), and vaccine response in immunocompromised and transplant patients (Dr. Hill).
They will support GeoVax's current and future development with its MVA and multi-antigen MVA vector platform for vaccines targeting biothreat pathogens and vulnerable populations, and future additions will support the company's oncology immunotherapy pipeline.
GeoVax aims to protect vulnerable or currently underserved populations including those from low- and middle-income countries (LMICs) and immunocompromised patients who have been underserved by traditional approaches or currently available vaccines.
The announcement was made on December 10, 2025, as reported by NEWMEDIAWIRE.
CEO David Dodd stated it strengthens GeoVax's position at the forefront of vaccine innovation, while CMO Dr. Kelly McKee noted it ensures clinical strategy is guided by cutting-edge immunology insight and global research expertise to protect vulnerable populations.
GeoVax is a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancers.
Curated from NewMediaWire
